Adastra Pharma’s Novel Glioma Therapy Achieves Positive Phase Ib Outcomes

Adastra Pharmaceuticals’ positive results from a Phase Ib trial of its therapy for recurrent high-grade glioblastomas suggest an effective treatment could be available within the next several years. If so, it would be a major breakthrough for patients affected by this lethal disease.